Dose-dependent effects of anthocyanin supplementation on platelet function in subjects with dyslipidemia: A randomized clinical trial

Dyslipidemia induces platelet hyperactivation and hyper-aggregation, which are linked to thrombosis. Anthocyanins could inhibit platelet function in vitro and in mice fed high-fat diets with their effects on platelet function in subjects with dyslipidemia remained unknown. This study aimed to invest...

Full description

Saved in:
Bibliographic Details
Published in:EBioMedicine 2021-08, Vol.70, p.103533, Article 103533
Main Authors: Tian, Zezhong, Li, Kongyao, Fan, Die, Zhao, Yimin, Gao, Xiaoli, Ma, Xilin, Xu, Lin, Shi, Yilin, Ya, Fuli, Zou, Jinchao, Wang, Ping, Mao, Yuheng, Ling, Wenhua, Yang, Yan
Format: Article
Language:English
Subjects:
Adult
Aged
Anthocyanins
Anthocyanins - administration & dosage
Anthocyanins - pharmacology
Anthocyanins - therapeutic use
Dietary Supplements
Dose-dependent effects
Dose-Response Relationship, Drug
Dyslipidemias - drug therapy
Female
Humans
Male
Middle Aged
Oxidative stress
P-Selectin - blood
Platelet Aggregation - drug effects
Platelet Aggregation Inhibitors - administration & dosage
Platelet Aggregation Inhibitors - pharmacology
Platelet Aggregation Inhibitors - therapeutic use
Platelet function
Platelet Glycoprotein GPIIb-IIIa Complex - metabolism
Randomized controlled trial
Reactive Oxygen Species - blood
Research Paper
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dyslipidemia induces platelet hyperactivation and hyper-aggregation, which are linked to thrombosis. Anthocyanins could inhibit platelet function in vitro and in mice fed high-fat diets with their effects on platelet function in subjects with dyslipidemia remained unknown. This study aimed to investigate the effects of different doses of anthocyanins on platelet function in individuals with dyslipidemia. A double-blind, randomized, controlled trial was conducted. Ninety-three individuals who were initially diagnosed with dyslipidemia were randomly assigned to placebo or 40, 80, 160 or 320 mg/day anthocyanin groups. The supplementations were anthocyanin capsules (Medox, Norway). Platelet aggregation by light aggregometry of platelet-rich plasma, P-selectin, activated GPⅡbⅢa, reactive oxygen species (ROS), and mitochondrial membrane potential were tested at baseline, 6 weeks and 12 weeks. Compared to placebo group, anthocyanins at 80 mg/day for 12 weeks reduced collagen-induced platelet aggregation (-3.39±2.36%) and activated GPⅡbⅢa (-8.25±2.45%) (P 
ISSN:2352-3964
2352-3964
DOI:10.1016/j.ebiom.2021.103533